Akero Therapeutics
A Principal Scientist at Akero Therapeutics supports analytical development and characterization activities for late-stage biologic development leading to licensure application submission. The role involves working closely with cross-functional teams to execute analytical studies, method development, and regulatory document drafting.
Headquarters
South San Francisco, California, United States
Company Size
11-50 employees
Founded
2017
Akero Therapeutics is a clinical-stage biopharmaceutical company focused on developing transformational therapies for metabolic dysfunction‑associated steatohepatitis (MASH) and related metabolic diseases. Their lead investigational candidate, efruxifermin (EFX), is an engineered FGF21‑based therapy designed to improve metabolic health and reduce liver disease in people with MASH. Akero advances programs through clinical development with the goal of addressing underlying metabolic drivers of liver disease and improving long‑term patient outcomes.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Akero Therapeutics.
35% above the average for this role
Novo Nordisk to acquire Akero Therapeutics for $5.2 billion
Oct 14, 2025
Senior Manager, Analytical Sciences
Summit Therapeutics,
Senior Manager or Associate Director, Analytical Development
GSK plc
Scientist II, Analytical Development
AbbVie
Senior Scientist, Analytical Development and Quality Control (Drug Product)
Nurix
Principal Research Scientist II, Analytical Lead, R&D
AbbVie
Associate Director of Analytical Development and CMC Statistics
Summit Therapeutics,